Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Strong Gametocytocidal Effect of Methylene Blue-Based Combination Therapy against Falciparum Malaria: A Randomised Controlled Trial
PLoS ONE, Volume 4, No. 5, Article e0005318, Year 2009
Notification
URL copied to clipboard!
Description
Background:With the availability of new preventive and curative interventions, global malaria control has been strengthened significantly in recent years. Drugs effective in reducing malaria gametocytaemia might contribute to local elimination and possible long-term eradication. We here report on the effects of methylene blue (MB)-based malaria combination therapy on gametocytaemia during a randomised-controlled trial in Burkina Faso.Methods:An open-label randomised controlled phase II study in 180 children aged 6-10 years with uncomplicated falciparum malaria was conducted in Nouna, north-western Burkina Faso. Children were randomised to MB-artesunate (AS), MB-amodiaquine (AQ), and AS-AQ (local standard of care). Overall follow-up was for 28 days, follow-up for gametocytaemia was for 14 days.Findings:The treatment groups were similar in baseline characteristics and there was only one loss to follow-up. Compared to AS-AQ, both MB-containing regimens were associated with significantly reduced gametocyte carrier rates during follow-up days 3, 7, and 14. This effect was seen both in patients with and without P. falciparum gametocytaemia at baseline.Interpretation:MB reveals pronounced gametocytocidal activity which appears to act against both existing and developing P. falciparum gametocytes. MB-based combination therapy thus has the potential to reduce transmission of P. falciparum malaria in endemic regions, which has important implications for future elimination and eradication strategies. Trial Registration: ClinicalTrials.gov NCT00354380. © 2009 Coulibaly et al.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC2673582/bin/pone.0005318.s001.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC2673582/bin/pone.0005318.s002.doc
Authors & Co-Authors
Coulibaly, Boubacar
Burkina Faso, Nouna
Centre de Recherche en Sante de Nouna
Zoungrana, Augustin
Burkina Faso, Nouna
Centre de Recherche en Sante de Nouna
Mockenhaupt, Frank Peter
Germany, Berlin
Charité – Universitätsmedizin Berlin
Schirmer, Rolf Heiner
Germany, Heidelberg
Universität Heidelberg
Klose, Christina
Germany, Heidelberg
Universität Heidelberg
Mansmann, Ulrich R.
Germany, Munich
Ludwig-maximilians-universität München
Meißner, Peter E.
Germany, Heidelberg
Universität Heidelberg
Müller, Olaf
Germany, Heidelberg
Universität Heidelberg
Statistics
Citations: 123
Authors: 8
Affiliations: 4
Identifiers
Doi:
10.1371/journal.pone.0005318
e-ISSN:
19326203
Research Areas
Infectious Diseases
Maternal And Child Health
Study Design
Randomised Control Trial
Cohort Study
Study Locations
Burkina Faso